Published in J Med Chem on January 12, 2006
Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev (2007) 4.87
Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry. Chem Rev (2009) 1.53
Engineering the substrate specificity of the DhbE adenylation domain by yeast cell surface display. Chem Biol (2013) 1.51
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
5'-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem (2007) 1.39
Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis. Nat Chem Biol (2009) 1.39
Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria. ChemMedChem (2008) 1.31
Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents. Org Lett (2006) 1.27
Mycobacterial phenolic glycolipid virulence factor biosynthesis: mechanism and small-molecule inhibition of polyketide chain initiation. Chem Biol (2007) 1.25
Biosynthetic analysis of the petrobactin siderophore pathway from Bacillus anthracis. J Bacteriol (2006) 1.22
A mechanism-based aryl carrier protein/thiolation domain affinity probe. J Am Chem Soc (2007) 1.22
Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J Med Chem (2008) 1.21
Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis. Bioorg Med Chem Lett (2008) 1.19
Comprehensive spectroscopic, steady state, and transient kinetic studies of a representative siderophore-associated flavin monooxygenase. J Biol Chem (2010) 1.10
Analyses of MbtB, MbtE, and MbtF suggest revisions to the mycobactin biosynthesis pathway in Mycobacterium tuberculosis. J Bacteriol (2012) 1.10
Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem Biol (2011) 1.08
Aryl acid adenylating enzymes involved in siderophore biosynthesis: fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening. Biochemistry (2008) 1.05
Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. Chembiochem (2008) 1.05
Baulamycins A and B, broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in Staphylococcus aureus and Bacillus anthracis. J Am Chem Soc (2014) 1.04
Biochemical and structural characterization of bisubstrate inhibitors of BasE, the self-standing nonribosomal peptide synthetase adenylate-forming enzyme of acinetobactin synthesis. Biochemistry (2010) 1.04
Selective inhibition of biotin protein ligase from Staphylococcus aureus. J Biol Chem (2012) 1.03
Exploiting ligand conformation in selective inhibition of non-ribosomal peptide synthetase amino acid adenylation with designed macrocyclic small molecules. J Am Chem Soc (2007) 1.02
Adenylating enzymes in Mycobacterium tuberculosis as drug targets. Curr Top Med Chem (2012) 1.00
Kinetic and inhibition studies of dihydroxybenzoate-AMP ligase from Escherichia coli. Biochemistry (2010) 1.00
Solution structure of Rv2377c-founding member of the MbtH-like protein family. Tuberculosis (Edinb) (2010) 1.00
Structural characterization and high-throughput screening of inhibitors of PvdQ, an NTN hydrolase involved in pyoverdine synthesis. ACS Chem Biol (2011) 1.00
Small molecule inhibition of microbial natural product biosynthesis-an emerging antibiotic strategy. Chem Soc Rev (2008) 0.98
Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice. Antimicrob Agents Chemother (2013) 0.97
Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. J Am Chem Soc (2010) 0.95
Development of a selective activity-based probe for adenylating enzymes: profiling MbtA Involved in siderophore biosynthesis from Mycobacterium tuberculosis. ACS Chem Biol (2012) 0.94
Stable analogues of OSB-AMP: potent inhibitors of MenE, the o-succinylbenzoate-CoA synthetase from bacterial menaquinone biosynthesis. Chembiochem (2011) 0.94
Mechanism and regulation of mycobactin fatty acyl-AMP ligase FadD33. J Biol Chem (2013) 0.92
A continuous kinetic assay for adenylation enzyme activity and inhibition. Anal Biochem (2010) 0.92
Iron trafficking as an antimicrobial target. Biometals (2009) 0.91
Characterization of peptide chain length and constituency requirements for YejABEF-mediated uptake of microcin C analogues. J Bacteriol (2011) 0.91
Small molecules with structural similarities to siderophores as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis. Bioorg Med Chem Lett (2008) 0.90
General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol (2014) 0.89
Selective inhibitors of bacterial phosphopantothenoylcysteine synthetase. J Am Chem Soc (2009) 0.89
Breaking a pathogen's iron will: Inhibiting siderophore production as an antimicrobial strategy. Biochim Biophys Acta (2015) 0.88
Mechanistic analysis of Mycobacterium tuberculosis Rv1347c, a lysine Nepsilon-acyltransferase involved in mycobactin biosynthesis. Arch Biochem Biophys (2008) 0.87
Structure-activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis. Bioorg Med Chem (2013) 0.86
Structural Biology of Nonribosomal Peptide Synthetases. Methods Mol Biol (2016) 0.86
Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters. Eur J Med Chem (2010) 0.85
Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis. J Med Chem (2015) 0.82
Synthesis of chromone, quinolone, and benzoxazinone sulfonamide nucleosides as conformationally constrained inhibitors of adenylating enzymes required for siderophore biosynthesis. J Org Chem (2013) 0.81
Quantitative three dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine and the aryl acid adenylating enzyme MbtA. J Med Chem (2008) 0.80
Cyclic diguanylate monophosphate directly binds to human siderocalin and inhibits its antibacterial activity. Nat Commun (2015) 0.80
Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists. J Med Chem (2013) 0.80
Non-nucleoside inhibitors of BasE, an adenylating enzyme in the siderophore biosynthetic pathway of the opportunistic pathogen Acinetobacter baumannii. J Med Chem (2013) 0.80
Improved Synthesis of Biotinol-5'-AMP: Implications for Antibacterial Discovery. ACS Med Chem Lett (2014) 0.80
Biotin Protein Ligase Is a Target for New Antibacterials. Antibiotics (Basel) (2016) 0.79
Investigation and conformational analysis of fluorinated nucleoside antibiotics targeting siderophore biosynthesis. J Org Chem (2015) 0.79
Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorg Med Chem (2014) 0.77
Synthesis of deuterium-labelled 5'-O-[N-(Salicyl)sulfamoyl]adenosine (Sal-AMS-d(4)) as an internal standard for quantitation of Sal-AMS. J Labelled Comp Radiopharm (2008) 0.77
Designed Small-Molecule Inhibitors of the Anthranilyl-CoA Synthetase PqsA Block Quinolone Biosynthesis in Pseudomonas aeruginosa. ACS Chem Biol (2016) 0.76
2-Aryl-8-aza-3-deazaadenosine analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in Mycobacterium tuberculosis. Bioorg Med Chem (2016) 0.75
Coupling Binding to Catalysis: Using Yeast Cell Surface Display to Select Enzymatic Activities. Methods Mol Biol (2015) 0.75
Chemotherapeutic interventions against tuberculosis. Pharmaceuticals (Basel) (2012) 0.75
Models for antitubercular activity of 5â-O-[(N-Acyl)sulfamoyl]adenosines. Sci Pharm (2010) 0.75
Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis. Bioorg Med Chem (2016) 0.75
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes. Bioorg Med Chem Lett (2016) 0.75
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Age and the epidemiology and pathogenesis of tuberculosis. Lancet (2010) 3.37
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
Structural and functional investigation of the intermolecular interaction between NRPS adenylation and carrier protein domains. Chem Biol (2012) 1.99
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis (2008) 1.67
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J Biol Chem (2003) 1.62
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem Biol (2011) 1.56
Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. ACS Med Chem Lett (2011) 1.54
The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol (2009) 1.53
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol (2002) 1.52
Engineering the substrate specificity of the DhbE adenylation domain by yeast cell surface display. Chem Biol (2013) 1.51
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A (2012) 1.48
Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog (2011) 1.45
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science (2012) 1.44
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol (2009) 1.43
Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry. J Am Soc Mass Spectrom (2003) 1.41
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
Crystal structure of 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate kinase from Salmonella typhimurium at 2.3 A resolution. Structure (2002) 1.39
5'-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem (2007) 1.39
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A (2013) 1.39
In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis (2005) 1.36
Impact of diabetes and smoking on mortality in tuberculosis. PLoS One (2013) 1.36
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother (2012) 1.32
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One (2013) 1.31
Expansion of the mycobacterial "PUPylome". Mol Biosyst (2009) 1.31
Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol (2012) 1.30
Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol (2010) 1.30
Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog (2011) 1.29
Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents. Org Lett (2006) 1.27
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology (2007) 1.26
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25
Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. Nat Chem Biol (2011) 1.23
Biosynthetic analysis of the petrobactin siderophore pathway from Bacillus anthracis. J Bacteriol (2006) 1.22
Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2012) 1.22
A mechanism-based aryl carrier protein/thiolation domain affinity probe. J Am Chem Soc (2007) 1.22
A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21
The three RelE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J Bacteriol (2010) 1.21
Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J Med Chem (2008) 1.21
Characterization and analysis of early enzymes for petrobactin biosynthesis in Bacillus anthracis. Biochemistry (2007) 1.21
Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today (2011) 1.21
Structure of PA1221, a nonribosomal peptide synthetase containing adenylation and peptidyl carrier protein domains. Biochemistry (2012) 1.19
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. J Bacteriol (2006) 1.17
Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun (2013) 1.16
Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem (2009) 1.15
Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2012) 1.13
Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol (2012) 1.13
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol (2010) 1.12
Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. J Am Chem Soc (2009) 1.12
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother (2013) 1.10